Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Top Estimates

Core Insights - Jazz Pharmaceuticals reported quarterly earnings of $6.61 per share, exceeding the Zacks Consensus Estimate of $5.47 per share, and showing an increase from $4.84 per share a year ago, resulting in an earnings surprise of 20.84% [1] - The company generated revenues of $1.05 billion for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 1.75% and increasing from $972.14 million year-over-year [2] - Jazz shares have underperformed the market, losing approximately 9.4% since the beginning of the year, while the S&P 500 has gained 21.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $6.05 on revenues of $1.08 billion, and for the current fiscal year, it is $19.52 on revenues of $4.04 billion [7] - The estimate revisions trend for Jazz is mixed, leading to a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Drugs industry, to which Jazz belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]